Curcumin inhibits the activity of GSK-3β to prevent AD in vitro

Chinese Pharmacological Bulletin

Volumn 25, Issue 11, 2009, Pages 1507-1512

  Zhang, Xiong ^a   Li, Yu ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; A ; Curcumin; CyclinD1; GSK 3 ; catenin

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA CATENIN; CURCUMIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 77349094277     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Boonen R A, VanTijn P, Zivkovic D. Wnt signaling in Alzheimer's disease: Up or down, that is the question[J]. Aging Res Rev, 2009,8:71-82.
2. Rockenstein E, Torrance M, Adame A, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3 beta signaling pathway in a transgenic model of AD are associated with reduced amyloid precursor protein phosphorylation [J]. J Neurosci, 2007,27(8):1981-1991.
3. Hu S, Begum A N, Jones M R, et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals[J]. Neurobiol Dis, 2009,33(2):193-206.
4. Chinese source
5. Li N, Liu G T. Glycogen synthase kinase-3 : an emerging therapeutic target for Alzheimer's disease [J]. Chin Pharmacol Bull, 2007,23(12):1544-8.
6. Hatchera H, Planalpb R, Cho J, et al. Curcumin: From ancient medicine to current clinical trials[J]. Cell Mol Life Sci, 2008,65(11):1631- 52.
7. Bustanji Y, Taha M O, Almasri I M, et al. Inhibition of glycogen synthase kinase by curcumin : investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation[J]. J Enzyme Inhib Med Chem, 2008,7:1.
8. Frame S, Cohen P, Biondi R M. A common phosphate bingding site explains the unique substrate specificity of GSK-3 and its inactivation by phosphorylation[J]. Mol Cell, 2001,7(6):1321-7.
9. Zhang Q G, Wang R, Khan M, et al. Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation J [J]. Neurosci, 2008,28(34): 8430-41.
10. Beaulieu J M, Marion S, Rodriguiz R M, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior[J]. Cell, 2008,132(1):125-36.
11. Park C H, Hahm E R, Park S, et al. The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling[J]. FEBS Lett, 2005,579(13):2965-71.
12. Chen A, Xu J. Activation of PPARγ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR[J]. Am J Physiol Gastrointest Liver Physiol, 2005,288:G447-56.
13. Vassar R. Beta-secretase, APP and Abeta in Alzheimer's disease [J]. Subcell Biochem, 2005,38:79-103.
14. Semeels L, Van Biervliet J, Craessaerts K, et al. Gamma-secretase heterogeneity in the Aph1 subunit : relevance for Alzheimer's Disease[J]. Science, 2009,324(5927):639-42.
15. Chinese source
16. Zhang H M, Zhang X, Li Y. The regulation of Curcumin on the amyloidogentic pathaway of APP in Alzheimer's disease[J]. Chin Pharmacol Bull, 2009,25(3):361-6.
17. Twomey C, McCarthy J V. Presenilin-1 is ah unprimed glycogen synthase kinase-3 beta substrate[J]. FEBS Lett, 2006,580(17):4015-20.
18. Tesco G, Tanzi R E. GSK-3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin : Effects of the D257/D385A and FAD-linked mutations[J]. Ann NY Acad Sci, 2000,920:227-32.